19.88
-1.97%
Close of 19 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $23.15bn
- Last close × shares
- Volume
- 9.2m
- Shares, 19 Nov 2026
- Dividend yield
- 2.50%
About Viatris
From its filings with the US Securities and Exchange Commission
Viatris is based in Canonsburg, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VTRS. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $14.30bn and a net loss of $3.51bn. At that date it held total assets of $37.19bn and shareholders' equity of $14.71bn.
Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.
Viatris’ executive management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders. The Company operates in more than 165 countries and territories with more than 30,000 employees. The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules, and what we believe is industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise. Viatris’ portfolio consists of generics (including complex products), globally recognized iconic brands, and an expanding portfolio of innovative medicines. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2025
- Brands $9.18bn · 64.4%
- Generics $5.07bn · 35.6%
- Lipitor ® $1.55bn · 10.9%
- Norvasc ® $709.9m · 5.0%
Latest on Viatris
Our reporting
Next results
Due on 25 Feb 2027. Analysts expect earnings of 0.60 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Viatris's ticker?
Viatris trades as VTRS on its US listing, under ISIN US92556V1061.
What was Viatris's last closing price?
19.88 on 19 Nov 2026. The figure is in USD and is never converted.
When does Viatris next report results?
Results are expected on 5 Nov 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.